• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Japan Pharmacovigilance Market

    ID: MRFR/Pharma/49692-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Japan Pharmacovigilance Market Research Report By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting), and By End-user (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Japan Pharmacovigilance Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    Japan Pharmacovigilance Market Summary

    The Japan Pharmacovigilance market is projected to grow significantly, reaching 1000 USD Million by 2035.

    Key Market Trends & Highlights

    Japan Pharmacovigilance Key Trends and Highlights

    • The market valuation for Japan Pharmacovigilance is estimated at 493.8 USD Million in 2024.
    • From 2025 to 2035, the market is expected to grow at a compound annual growth rate of 6.63%.
    • By the year 2035, the market is anticipated to reach a total value of 1000 USD Million.
    • Growing adoption of advanced data analytics due to increasing regulatory requirements is a major market driver.

    Market Size & Forecast

    2024 Market Size 493.8 (USD Million)
    2035 Market Size 1000 (USD Million)
    CAGR (2025-2035) 6.63%

    Major Players

    Daiichi Sankyo, Pfizer, Mitsubishi Tanabe Pharma, Merck, AstraZeneca, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Takeda, Chugai Pharmaceutical, Johnson & Johnson, Otsuka Pharmaceutical, AbbVie, Sanofi, Novartis

    Japan Pharmacovigilance Market Trends

    The expanding complexity of medication regimens and the growing demand for patient safety monitoring are two major drivers propelling the Japan Pharmacovigilance Market. The negative effects of drugs are receiving more attention in Japan due to the country's ageing population and growing prevalence of chronic illnesses.

    Pharmaceutical businesses operating in the region prioritise strong pharmacovigilance systems because the Ministry of Health, Labour, and Welfare aggressively stresses their relevance in ensuring medication safety.

    Adopting cutting-edge technologies and data analytics can help seize market opportunities. Businesses can improve their pharmacovigilance procedures by using real-time data to monitor adverse effects, thanks to the Japanese government's backing of efforts for digital health and electronic health records.

    This change not only supports Japan's dedication to healthcare innovation, but it also offers businesses an opportunity to put in place more effective monitoring systems. Pharmacovigilance is moving towards more integrated systems, where businesses and regulatory bodies work together to exchange data and insights, according to recent developments.

    The detection and management of risks related to pharmaceuticals on the market are improved by this partnership. As seen by the adoption of new standards intended to improve transparency and response times for reporting adverse medication reactions, Japan's regulatory environment is changing.

    Furthermore, as clinical trials become increasingly globalised, Japanese businesses must become more flexible and adaptable to a global market that expects greater efficacy and safety standards.

    Japan Pharmacovigilance Market Drivers

    Market Segment Insights

    Get more detailed insights about Japan Pharmacovigilance Market Research Report - Forecast to 2035

    Regional Insights

    Key Players and Competitive Insights

    The Japan Pharmacovigilance Market is a critical sector that ensures the safety and efficacy of pharmaceutical products post-marketing. It plays a vital role in monitoring drug safety, collecting data on adverse drug reactions, and conducting risk assessments to protect public health.

    The competitive landscape of this market is shaped by various local and global entities striving to enhance their market presence through advanced technologies, regulatory compliance, and comprehensive drug monitoring systems.

    As a result, companies in this market must navigate a complex regulatory environment while also focusing on innovative solutions to meet the increasing demands for drug safety and real-time data analysis.

    The growing emphasis on patient safety and the rising need for stringent regulatory frameworks further intensify the competition among market players, driving them to invest in robust pharmacovigilance offerings and strategic partnerships.

    Daiichi Sankyo stands out in the Japan Pharmacovigilance Market due to its deep-rooted commitment to ensuring drug safety and compliance with regulatory standards. As a leading Japanese pharmaceutical company, it has a well-established pharmacovigilance system that actively monitors and evaluates drug safety profiles, ensuring swift reporting of adverse events and thorough assessment of risks.

    The company's strong reputation is reinforced by its extensive research and development capabilities, allowing it to rapidly adapt to changes in regulatory requirements and incorporate advanced technologies into its pharmacovigilance processes.

    Daiichi Sankyo is recognized for its robust data management and analysis services, which enhance the efficiency of safety reporting and risk management. This strong foundation enables the company to maintain a prominent position in the pharmacovigilance space within Japan while continuing to build trust with both healthcare professionals and regulatory authorities.

    Pfizer also holds a significant position in the Japan Pharmacovigilance Market with its comprehensive suite of services aimed at ensuring drug safety. Known for its leading pharmaceutical products and strong market presence, Pfizer's pharmacovigilance operations in Japan are characterized by advanced technology implementation and a proactive approach to safety monitoring.

    The company invests heavily in data analytics and risk management strategies, which help to promptly identify safety concerns associated with its products. Pfizer's strengths lie in its global reach and extensive experience in the pharmaceutical industry, enabling it to effectively leverage international safety data while adhering to local regulatory requirements.

    Furthermore, Pfizer's strategic mergers and acquisitions have bolstered its market presence in Japan, allowing the company to diversify its portfolio and enhance its pharmacovigilance capabilities.

    By continuously focusing on innovation and compliance, Pfizer remains a formidable competitor in the Japanese pharmacovigilance sector, demonstrating a commitment to safeguarding public health through rigorous monitoring of its pharmaceutical offerings.

    Key Companies in the Japan Pharmacovigilance Market market include

    Industry Developments

    The Japan Pharmacovigilance Market has seen significant developments in recent months, particularly with the increasing involvement of major pharmaceutical companies.

    Companies such as Daiichi Sankyo and Takeda are enhancing their pharmacovigilance efforts through innovative technologies and increased regulatory compliance, responding to the Japanese government's commitment to healthcare systems improvement.

    In a notable merger, AstraZeneca and Daiichi Sankyo have been working together on the commercialization of their oncology product, enhancing both firms' presence in the market as of April 2023.

    Moreover, the market has witnessed a growing trend in utilizing Artificial Intelligence and machine learning for adverse event reporting and data management, with companies like Pfizer and Roche leading research initiatives to streamline these processes.

    The Japanese Pharmacovigilance Market is expected to grow robustly, influenced by advancements in digital health solutions and the rising focus on patient safety metrics as mandated by local regulations.

    In recent years, there has been an increased awareness and management of drug safety issues, intensifying scrutiny and collaboration among pharmaceutical firms such as Merck, GlaxoSmithKline, and Bristol-Myers Squibb to ensure ongoing compliance with safety standards and regulations that are being revised in response to global health challenges.

    Market Segmentation

    Outlook

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 465.62(USD Million)
    MARKET SIZE 2024 493.75(USD Million)
    MARKET SIZE 2035 1000.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.626% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Daiichi Sankyo, Pfizer, Mitsubishi Tanabe Pharma, Merck, AstraZeneca, Roche, BristolMyers Squibb, GlaxoSmithKline, Takeda, Chugai Pharmaceutical, Johnson & Johnson, Otsuka Pharmaceutical, AbbVie, Sanofi, Novartis
    SEGMENTS COVERED Service Type, Deployment Mode, Source, End User
    KEY MARKET OPPORTUNITIES Increasing regulatory compliance needs, Expansion of biotech firms, Integration of AI technologies, Rising demand for real-time monitoring, Growth in adverse event reporting
    KEY MARKET DYNAMICS regulatory compliance requirements, increasing adverse drug reactions, growing emphasis on patient safety, technological advancements in reporting, rise in pharmacovigilance outsourcing
    COUNTRIES COVERED Japan

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected market size of the Japan Pharmacovigilance Market in 2024?

    The Japan Pharmacovigilance Market is expected to be valued at 493.75 USD Million in 2024.

    What will be the market value of the Japan Pharmacovigilance Market in 2035?

    By 2035, the Japan Pharmacovigilance Market is projected to reach a value of 1000.0 USD Million.

    What is the compound annual growth rate (CAGR) of the Japan Pharmacovigilance Market from 2025 to 2035?

    The expected CAGR for the Japan Pharmacovigilance Market from 2025 to 2035 is 6.626%.

    What are the major service types provided in the Japan Pharmacovigilance Market?

    The major service types include Adverse Event Reporting, Risk Assessment, Data Mining, and Pharmacovigilance Consulting.

    How much revenue is the Adverse Event Reporting segment expected to generate in 2035?

    The Adverse Event Reporting segment is projected to generate 300.0 USD Million by 2035.

    Which key players are dominating the Japan Pharmacovigilance Market?

    Key players in the market include Daiichi Sankyo, Pfizer, Mitsubishi Tanabe Pharma, and Merck among others.

    What is the anticipated value of the Risk Assessment segment in 2024?

    The Risk Assessment segment is expected to be valued at 120.0 USD Million in 2024.

    What is the projected market size for the Data Mining segment by 2035?

    The Data Mining segment is projected to reach 200.0 USD Million by 2035.

    What key trend is influencing the Japan Pharmacovigilance Market recently?

    Increasing regulatory requirements for drug safety monitoring are emerging as a significant trend in the market.

    What revenue does the Pharmacovigilance Consulting segment expect to achieve in 2035?

    The Pharmacovigilance Consulting segment is anticipated to achieve a revenue of 260.0 USD Million in 2035.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. Japan Pharmacovigilance Market, BY Service Type (USD Million)
    45. Adverse Event Reporting
    46. Risk Assessment
    47. Data Mining
    48. Pharmacovigilance Consulting
    49. Japan Pharmacovigilance Market, BY Deployment Mode (USD Million)
    50. Cloud-Based
    51. On-Premise
    52. Japan Pharmacovigilance Market, BY Source (USD Million)
    53. Spontaneous Reporting
    54. Literature Reports
    55. Scheduled Reporting
    56. Japan Pharmacovigilance Market, BY End User (USD Million)
    57. Pharmaceutical Companies
    58. Biotechnology Companies
    59. Contract Research Organizations
    60. Competitive Landscape
    61. Overview
    62. Competitive Analysis
    63. Market share Analysis
    64. Major Growth Strategy in the Pharmacovigilance Market
    65. Competitive Benchmarking
    66. Leading Players in Terms of Number of Developments in the Pharmacovigilance Market
    67. Key developments and growth strategies
    68. New Product Launch/Service Deployment
    69. Merger & Acquisitions
    70. Joint Ventures
    71. Major Players Financial Matrix
    72. Sales and Operating Income
    73. Major Players R&D Expenditure. 2023
    74. Company Profiles
    75. Daiichi Sankyo
    76. Financial Overview
    77. Products Offered
    78. Key Developments
    79. SWOT Analysis
    80. Key Strategies
    81. Pfizer
    82. Financial Overview
    83. Products Offered
    84. Key Developments
    85. SWOT Analysis
    86. Key Strategies
    87. Mitsubishi Tanabe Pharma
    88. Financial Overview
    89. Products Offered
    90. Key Developments
    91. SWOT Analysis
    92. Key Strategies
    93. Merck
    94. Financial Overview
    95. Products Offered
    96. Key Developments
    97. SWOT Analysis
    98. Key Strategies
    99. AstraZeneca
    100. Financial Overview
    101. Products Offered
    102. Key Developments
    103. SWOT Analysis
    104. Key Strategies
    105. Roche
    106. Financial Overview
    107. Products Offered
    108. Key Developments
    109. SWOT Analysis
    110. Key Strategies
    111. BristolMyers Squibb
    112. Financial Overview
    113. Products Offered
    114. Key Developments
    115. SWOT Analysis
    116. Key Strategies
    117. GlaxoSmithKline
    118. Financial Overview
    119. Products Offered
    120. Key Developments
    121. SWOT Analysis
    122. Key Strategies
    123. Takeda
    124. Financial Overview
    125. Products Offered
    126. Key Developments
    127. SWOT Analysis
    128. Key Strategies
    129. Chugai Pharmaceutical
    130. Financial Overview
    131. Products Offered
    132. Key Developments
    133. SWOT Analysis
    134. Key Strategies
    135. Johnson & Johnson
    136. Financial Overview
    137. Products Offered
    138. Key Developments
    139. SWOT Analysis
    140. Key Strategies
    141. Otsuka Pharmaceutical
    142. Financial Overview
    143. Products Offered
    144. Key Developments
    145. SWOT Analysis
    146. Key Strategies
    147. AbbVie
    148. Financial Overview
    149. Products Offered
    150. Key Developments
    151. SWOT Analysis
    152. Key Strategies
    153. Sanofi
    154. Financial Overview
    155. Products Offered
    156. Key Developments
    157. SWOT Analysis
    158. Key Strategies
    159. Novartis
    160. Financial Overview
    161. Products Offered
    162. Key Developments
    163. SWOT Analysis
    164. Key Strategies
    165. References
    166. Related Reports
    167. Japan Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY SERVICE TYPE, 2019-2035 (USD Billions)
    168. Japan Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY DEPLOYMENT MODE, 2019-2035 (USD Billions)
    169. Japan Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY SOURCE, 2019-2035 (USD Billions)
    170. Japan Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    171. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    172. ACQUISITION/PARTNERSHIP
    173. MARKET SYNOPSIS
    174. JAPAN PHARMACOVIGILANCE MARKET ANALYSIS BY SERVICE TYPE
    175. JAPAN PHARMACOVIGILANCE MARKET ANALYSIS BY DEPLOYMENT MODE
    176. JAPAN PHARMACOVIGILANCE MARKET ANALYSIS BY SOURCE
    177. JAPAN PHARMACOVIGILANCE MARKET ANALYSIS BY END USER
    178. KEY BUYING CRITERIA OF PHARMACOVIGILANCE MARKET
    179. RESEARCH PROCESS OF MRFR
    180. DRO ANALYSIS OF PHARMACOVIGILANCE MARKET
    181. DRIVERS IMPACT ANALYSIS: PHARMACOVIGILANCE MARKET
    182. RESTRAINTS IMPACT ANALYSIS: PHARMACOVIGILANCE MARKET
    183. SUPPLY / VALUE CHAIN: PHARMACOVIGILANCE MARKET
    184. PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2025 (% SHARE)
    185. PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2019 TO 2035 (USD Billions)
    186. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2025 (% SHARE)
    187. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2019 TO 2035 (USD Billions)
    188. PHARMACOVIGILANCE MARKET, BY SOURCE, 2025 (% SHARE)
    189. PHARMACOVIGILANCE MARKET, BY SOURCE, 2019 TO 2035 (USD Billions)
    190. PHARMACOVIGILANCE MARKET, BY END USER, 2025 (% SHARE)
    191. PHARMACOVIGILANCE MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    192. BENCHMARKING OF MAJOR COMPETITORS

    Japan Pharmacovigilance Market Segmentation

     

     

     

    • Pharmacovigilance Market By Service Type (USD Million, 2019-2035)

      • Adverse Event Reporting
      • Risk Assessment
      • Data Mining
      • Pharmacovigilance Consulting

     

    • Pharmacovigilance Market By Deployment Mode (USD Million, 2019-2035)

      • Cloud-Based
      • On-Premise

     

    • Pharmacovigilance Market By Source (USD Million, 2019-2035)

      • Spontaneous Reporting
      • Literature Reports
      • Scheduled Reporting

     

    • Pharmacovigilance Market By End User (USD Million, 2019-2035)

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials